ArticleBMC public health2026
Efficacy of a WhatsApp-based program for nicotine and tobacco cessation among young people: study protocol for a randomized controlled trial.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNicotine and tobacco products are widely used by adolescents and young adults in Switzerland. At the same time, WhatsApp is one of the most frequently used digital communication platforms by this age group. Delivering individually tailored, evidence-based coaching messages via WhatsApp is a promising way to support young people in quitting nicotine use. This study protocol outlines a randomized controlled trial to test the efficacy of a semi-automated, WhatsApp-based intervention program to support nicotine cessation and reduction in adolescents and young adults.
methodsA two-arm, parallel-group, randomized controlled trial will be conducted to test the efficacy of NicotineFreeCoach compared to a waitlist control group. Participants for the study will be recruited both online and offline and will be assessed at the beginning of the study and at follow-ups after three and six months. During 12 weeks, participants in the intervention group will receive individually tailored WhatsApp messages designed to motivate them to stop or reduce their nicotine use. These messages will provide advice on dealing with cravings and stressful situations, as well as tips on quitting or reducing nicotine use. They will also have the opportunity to ask a counsellor individual questions via a separate WhatsApp channel. Participants in the control group will not initially have the opportunity to take part in the program, but will be invited to do so after completing the six-month survey. The study will involve 870 regular nicotine users aged 16–30, including those who use tobacco cigarettes, vapes, snus or multiple nicotine products. The primary outcome will be the seven-day point prevalence of nicotine abstinence in the follow-up survey after six months. Secondary outcomes will include the quantity and frequency of nicotine use, intention to quit and self-efficacy to do so, quality of life and alcohol use. DISCUSSION: This is the first randomized controlled study to test the efficacy of an instant messaging-based coaching program in supporting young people to quit tobacco and nicotine use. It provides a scientifically sound evaluation of the effectiveness of NicotineFreeCoach in Switzerland, and of WhatsApp-based coaching programs in promoting healthy behavior more broadly. If this approach proves effective, it could easily be implemented in various settings to reach large numbers of young people in a cost-effective way.
trial registrationISRCTN16197153 (registration date 20251209).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.